Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for the Secondary Prevention of Recurrent Pouchitis
NCT06312683Phase 4Recruiting
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Jul 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rifaximin in pouchitis, sponsored by University of North Carolina at Chapel Hill. Started Jul 2024; status: recruiting.
02
Drugs
rifaximin
03
Conditions
pouchitis
Beyond the preview
Go deeper on NCT06312683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06312683.